291 related articles for article (PubMed ID: 22079984)
1. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation.
Chung YC; Bok E; Huh SH; Park JY; Yoon SH; Kim SR; Kim YS; Maeng S; Park SH; Jin BK
J Immunol; 2011 Dec; 187(12):6508-17. PubMed ID: 22079984
[TBL] [Abstract][Full Text] [Related]
2. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease.
Huh SH; Chung YC; Piao Y; Jin MY; Son HJ; Yoon NS; Hong JY; Pak YK; Kim YS; Hong JK; Hwang O; Jin BK
J Immunol; 2011 Jul; 187(2):960-9. PubMed ID: 21685323
[TBL] [Abstract][Full Text] [Related]
3. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Price DA; Martinez AA; Seillier A; Koek W; Acosta Y; Fernandez E; Strong R; Lutz B; Marsicano G; Roberts JL; Giuffrida A
Eur J Neurosci; 2009 Jun; 29(11):2177-86. PubMed ID: 19490092
[TBL] [Abstract][Full Text] [Related]
4. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation.
Chung YC; Kim SR; Park JY; Chung ES; Park KW; Won SY; Bok E; Jin M; Park ES; Yoon SH; Ko HW; Kim YS; Jin BK
Neuropharmacology; 2011 May; 60(6):963-74. PubMed ID: 21288472
[TBL] [Abstract][Full Text] [Related]
5. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease.
Chung YC; Kim SR; Jin BK
J Immunol; 2010 Jul; 185(2):1230-7. PubMed ID: 20566832
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids prevent lipopolysaccharide-induced neurodegeneration in the rat substantia nigra in vivo through inhibition of microglial activation and NADPH oxidase.
Chung ES; Bok E; Chung YC; Baik HH; Jin BK
Brain Res; 2012 Apr; 1451():110-6. PubMed ID: 22436849
[TBL] [Abstract][Full Text] [Related]
7. Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson's Disease.
Wi R; Chung YC; Jin BK
J Immunol Res; 2020; 2020():5093493. PubMed ID: 33062722
[TBL] [Abstract][Full Text] [Related]
8. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
[TBL] [Abstract][Full Text] [Related]
9. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
Zhang W; Wang T; Qin L; Gao HM; Wilson B; Ali SF; Zhang W; Hong JS; Liu B
FASEB J; 2004 Mar; 18(3):589-91. PubMed ID: 14734632
[TBL] [Abstract][Full Text] [Related]
11. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
Wu DC; Jackson-Lewis V; Vila M; Tieu K; Teismann P; Vadseth C; Choi DK; Ischiropoulos H; Przedborski S
J Neurosci; 2002 Mar; 22(5):1763-71. PubMed ID: 11880505
[TBL] [Abstract][Full Text] [Related]
12. Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease.
Ren B; Zhang YX; Zhou HX; Sun FW; Zhang ZF; Wei Z; Zhang CY; Si DW
J Neurol Sci; 2015 Jan; 348(1-2):142-52. PubMed ID: 25491263
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
[TBL] [Abstract][Full Text] [Related]
14. CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease.
Chung YC; Shin WH; Baek JY; Cho EJ; Baik HH; Kim SR; Won SY; Jin BK
Exp Mol Med; 2016 Jan; 48(1):e205. PubMed ID: 27534533
[TBL] [Abstract][Full Text] [Related]
15. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
[TBL] [Abstract][Full Text] [Related]
16. Transient receptor potential vanilloid subtype 1 contributes to mesencephalic dopaminergic neuronal survival by inhibiting microglia-originated oxidative stress.
Park ES; Kim SR; Jin BK
Brain Res Bull; 2012 Nov; 89(3-4):92-6. PubMed ID: 22796104
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
Moon M; Kim HG; Hwang L; Seo JH; Kim S; Hwang S; Kim S; Lee D; Chung H; Oh MS; Lee KT; Park S
Neurotox Res; 2009 May; 15(4):332-47. PubMed ID: 19384567
[TBL] [Abstract][Full Text] [Related]
18. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
19. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
[TBL] [Abstract][Full Text] [Related]
20. Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity.
Zhang D; Hu X; Wei SJ; Liu J; Gao H; Qian L; Wilson B; Liu G; Hong JS
J Neuroinflammation; 2008 May; 5():21. PubMed ID: 18507839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
